Many chemotherapy regimens used today require the support of a granulocyte–colony-stimulating factor for the prevention of life-threatening neutropenia. In March 2015, a delivery method was introduced for Neulasta® (pegfilgrastim) through an on-body injector (Onpro®), which may eliminate the need for patients to return for injection after chemotherapy, increase workflow, and allow more patients to be seen. The purpose of this study was to monitor the implementation of the Onpro delivery system in an outpatient facility.
AT A GLANCE
- The administration of pegfilgrastim via an on-body injector is a safe and effective alternative to manual injections.
- The use of on-body injectors is associated with high patient satisfaction.
- Patient use of on-body injectors has improved nursing unit workflow.